Cas no 23541-50-6 (Daunorubicin hydrochloride)

Daunorubicin hydrochloride is an anthracycline antibiotic widely used in chemotherapy, particularly for treating acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Its mechanism of action involves intercalation into DNA, inhibiting topoisomerase II and disrupting nucleic acid synthesis, leading to cytotoxic effects in rapidly dividing cells. The hydrochloride salt form enhances solubility, facilitating intravenous administration. Key advantages include its established efficacy in induction therapy, synergistic potential with other antineoplastic agents, and well-characterized pharmacokinetics. Proper handling is essential due to its vesicant properties and potential cardiotoxicity. Daunorubicin hydrochloride remains a critical component in standardized chemotherapeutic regimens for hematologic malignancies.

Daunorubicin hydrochloride structure

Product Name:Daunorubicin hydrochloride

CAS No:23541-50-6

MF:C₂₇H₃₀ClNO₁₀

MW:563.9808

MDL:MFCD04974507

CID:52319

PubChem ID:253661912

Update Time:2025-12-31

Daunorubicin hydrochloride Chemical and Physical Properties

Names and Identifiers

- daunomycin hydrochloride
- Daunorubicin hydrochloride
- rubidomycin hydrochloride
- Daunorubicin, HCl
- DAUNOMYCIN
- DaunoMycin, Monohydrochloride
- Daunorubicin (hydrochloride)
- Daunorubicin ? HCl (Daunomycin ? HCl)
- Daunorubicin hydrochloride(BICINS)
- Daunorubicinol hydrochloride
- Cerubidine
- Dau hydrochloride
- daunoblastin
- daunoblastina
- DAUNOBLASTINE
- DAUNOMYCIN HCL
- DAUNOMYCINE HCL
- Hydroxydaunorubicin Hydrochloride
- ndc0082-4155
- ondena
- RP 13057 Hydrochloride
- RP-13057 Hydrochloride
- WP900 HYDROCHLORIDE
- (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
- Daunorubicin HCl
- Rubomycin
- Daunomycin chlorohydrate
- Daunomycin, hydrochloride
- UD984I04LZ
- daunomycin hydrochloride,Daunorubicin hydrochloride,rubidomycin hydrochloride,Daunorubicin, HCl,DAUNOMYCIN,DaunoMycin, Monohydrochloride,Daunorubicin (hydrochloride),Daunorubicin ? HCl (Daunomycin ? HCl)
- (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside hydrochloride
- DAUNORUBICIN HYDROCHLORIDE (USP IMPURITY)
- s3035
- WP900 hydrochloride, >=95% (HPLC), solid
- 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S,10S)-
- (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside hydrochloride
- CAS-23541-50-6
- DAUNORUBICIN HYDROCHLORIDE (MART.)
- FI 6339 HYDROCHLORIDE
- 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride
- NCGC00024246-03
- DTXSID0033382
- FI 6339 [as the base]
- FI-6339 HYDROCHLORIDE
- NDC 0082-4155
- AKOS015920259
- EX-A2649
- Daunorubicin Hydrochloride; RP 13057 Hydrochloride; Daunomycin
- KS-5149
- MLS001336042
- Daunorubicin HCl (Daunomycin HCl)
- Daunorubicin hydrochloride (JP18/USP)
- DAUNORUBICIN HYDROCHLORIDE [JAN]
- MLS002222263
- (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
- Cloridrato de Daunorubicina
- DAUNORUBICIN HYDROCHLORIDE [USP IMPURITY]
- SCHEMBL4444
- SMR000768722
- Tox21_201159
- CS-1271
- (2S,4S)-2-Acetyl-4-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-2,5,12-trihydroxy-7-methoxy-1,2,3,4-tetrahydrotetracene-6,11-dione monohydrochloride
- SR-05000001600
- HB4376
- DAUNORUBICIN HYDROCHLORIDE [WHO-DD]
- DAUNORUBICIN HYDROCHLORIDE [MART.]
- Hydrochloride, Daunorubicin
- DAUNORUBICIN HYDROCHLORIDE [USAN]
- (8S,10S)-8-acetyl-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
- DAUNORUBICIN HYDROCHLORIDE [USP-RS]
- 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trhydroxy-1-methoxy-, hydrochloride, (8S,10S)-
- Daunorubicin hydrochloride (USAN:USP:JAN)
- CHEBI:31456
- SR-01000000033-6
- SR-05000001600-3
- (8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride
- L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride
- 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-
- AI3-44887
- Daunorubicin.HCl
- Cerubidine (TN)
- UNII-UD984I04LZ
- SMR000058559
- NS00084572
- Daunorubicin hydrochloride [USAN:USP:JAN]
- DaunoXome
- Q27291034
- (8S,10S)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyransoyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride
- DAUNORUBICIN HYDROCHLORIDE [ORANGE BOOK]
- (8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
- DAUNORUBICIN HYDROCHLORIDE [VANDF]
- DAUNORUBICIN HYDROCHLORIDE (USP-RS)
- RP 13057 [AS THE BASE)
- Daunorubicin hydrochloride, >=90% (HPLC)
- CCRIS 915
- NCGC00258711-01
- Daunorubicin,(S)
- SR-01000000033
- Daunorubicin (as hydrochloride)
- RP 13057 [as the base]
- (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE HYDROCHLORIDE
- Daunomycin; RP 13057; Rubidomycin
- CHEMBL1563
- CCG-39942
- Daunorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
- D01264
- DAUNORUBICIN HYDROCHLORIDE (EP MONOGRAPH)
- HY-13062
- DAUNORUBICIN HYDROCHLORIDE [USP MONOGRAPH]
- DTXCID8013382
- RP-13057
- 5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-, HYDROCHLORIDE
- Daunorubicin HCl- Bio-X
- DAUNORUBICIN HYDROCHLORIDE [EP MONOGRAPH]
- DAUNORUBICIN HYDROCHLORIDE (USP MONOGRAPH)
- MLS000069508
- C27H29NO10.HCl
- BD164356
- EINECS 245-723-4
- MFCD04974507
- NSC-82151
- Daunorubicini Hydrochloridum
- DAUNORUBICIN HYDROCHLORIDE [MI]
- Daunorubicin hydrochloride, meets USP testing specifications
- 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl))oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride
- Daunorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
- 23541-50-6
- Rubilem
- MDL： MFCD04974507
- Inchi： 1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1
- InChI Key： GUGHGUXZJWAIAS-QQYBVWGSSA-N
- SMILES： Cl[H].O([C@@]1([H])C([H])([H])[C@@]([H])([C@@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])N([H])[H])[C@]1([H])C2C(=C3C(C4C(=C([H])C([H])=C([H])C=4C(C3=C(C=2C([H])([H])[C@@](C(C([H])([H])[H])=O)(C1([H])[H])O[H])O[H])=O)OC([H])([H])[H])=O)O[H]
- BRN： 4229221

Computed Properties

Exact Mass: 563.15600
Monoisotopic Mass: 563.156
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 6
Hydrogen Bond Acceptor Count: 11
Heavy Atom Count: 39
Rotatable Bond Count: 4
Complexity: 960
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 6
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: 54
Topological Polar Surface Area: 186
Molecular Weight: 564.0

Experimental Properties

Color/Form: solid
Melting Point: 194-200°C
Boiling Point: 770 °C at 760 mmHg
Flash Point: 419.5 °C
Solubility: Soluble (NTP, 1992)
Stability/Shelf Life: Stability
PSA: 185.84000
LogP: 2.53120
Merck: 2832
Sensitiveness: Hygroscopic
Specific Rotation: +250.0 to +275.0 ° (c=0.15, MeOH)
λmax: 477(H2O)(lit.)
Solubility: Not determined
Vapor Pressure: No data available

Daunorubicin hydrochloride Security Information

Symbol:
Prompt：dangerous
Signal Word：Danger
Hazard Statement： H301-H317-H334-H351
Warning Statement： P201-P202-P261-P264-P270-P272-P280-P284-P301+P310+P330-P302+P352+P333+P313+P362+P364-P304+P340+P342+P311-P308+P313-P405-P501
Hazardous Material transportation number：UN 2811
WGK Germany：3
Hazard Category Code： 22-40-42/43
Safety Instruction： S22-S36/37-S45
FLUKA BRAND F CODES：3-10
RTECS：HB7878000
Hazardous Material Identification：
HazardClass：6.1
PackingGroup：III
Toxicity：LD50 in mice (mg/kg): 26 i.v. (DiMarco, 1969)
Storage Condition：4°C, protect from light
Safety Term：6.1(b)
Packing Group：III
Risk Phrases：R22; R40; R42/43
Packing Group：III
Hazard Level：6.1(b)

Daunorubicin hydrochloride Customs Data

HS CODE：2932999099
Customs Data：

China Customs Code:
2932999099

Overview:

2932999099. Other heterocyclic compounds containing only oxygen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to

Summary:

2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Daunorubicin hydrochloride Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.	CB03404-0.1g	Daunorubicin hydrochloride	23541-50-6	97%	0.1g	127.00	2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.	CB03404-0.25g	Daunorubicin hydrochloride	23541-50-6	97%	0.25g	254.00	2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.	CB03404-1g	Daunorubicin hydrochloride	23541-50-6	97%	1g	751.00	2021-06-01
SHANG HAI XIANG HUI YI YAO Technology Co., Ltd.	CB03404-5g	Daunorubicin hydrochloride	23541-50-6	97%	5g	2936.00	2021-06-01
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	D4532-100MG	Daunorubicin Hydrochloride	23541-50-6	>98.0%(N)	100mg	￥260.00	2024-04-17
S e l l e c k ZHONG GUO	S3035-10mM (1mL in DMSO)	Daunorubicin HCl	23541-50-6	99.98%	10mM (1mL in DMSO)	￥727.52	2023-09-15
S e l l e c k ZHONG GUO	S3035-10mg	Daunorubicin HCl	23541-50-6	99.98%	10mg	￥579.56	2023-09-15
S e l l e c k ZHONG GUO	S3035-50mg	Daunorubicin HCl	23541-50-6	99.98%	50mg	￥2188.15	2023-09-15
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R011172-25mg	Daunorubicin hydrochloride	23541-50-6	90%	25mg	￥574	2023-09-09
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R011172-5mg	Daunorubicin hydrochloride	23541-50-6	90%	5mg	￥207	2023-09-09

Daunorubicin hydrochloride Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:23541-50-6)鹽酸柔紅霉素

Order Number:LE27066869;LE404

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 13:04

Price ($):discuss personally

Email:[email protected]

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:23541-50-6)Daunorubicin hydrochloride

Order Number:sfd15492

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:37

Price ($):discuss personally

Email:[email protected]

Product Official Link

Daunorubicin hydrochloride Spectrogram

13C NMR

1H NMR

300 MHz

DMSO

Daunorubicin hydrochloride Related Literature

1. Surface modified multifunctional ZnFe2O4 nanoparticles for hydrophobic and hydrophilic anti-cancer drug molecule loading

Debabrata Maiti,Arindam Saha,Parukuttyamma Sujatha Devi Phys. Chem. Chem. Phys. 2016 18 1439
2. Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo

M. H. Li,H. Yu,T. F. Wang,N. D. Chang,J. Q. Zhang,D. Du,M. F. Liu,S. L. Sun,R. Wang,H. Q. Tao,S. L. Geng,Z. Y. Shen,Q. Wang,H. S. Peng J. Mater. Chem. B 2014 2 1619
3. The lectin binding and targetable cellular uptake of lipid-coated polysaccharide microcapsules

Wei Qi,Anhe Wang,Yang Yang,Mingchun Du,Marie Noelle Bouchu,Paul Boullanger,Junbai Li J. Mater. Chem. 2010 20 2121
4. Synthesis of the first POSS cage–anthracycline conjugates via amide bonds

Kinga Piorecka,Ewa Radzikowska,Jan Kurjata,Krystyna Rozga-Wijas,Wlodzimierz A. Stanczyk,Ewelina Wielgus New J. Chem. 2016 40 5997
5. Binding affinity data of DNA aptamers for therapeutic anthracyclines from microscale thermophoresis and surface plasmon resonance spectroscopy

Stephan Sass,Walter F. M. St?cklein,Anja Klevesath,Jeanne Hurpin,Marcus Menger,Carsten Hille Analyst 2019 144 6064

Related Categories

Additional information on Daunorubicin hydrochloride

Daunorubicin Hydrochloride: A Comprehensive Overview of its Applications and Recent Research Developments

Daunorubicin hydrochloride, with the CAS number 23541-50-6, is a well-established anthracycline antibiotic widely recognized for its significant role in the treatment of various hematological malignancies and solid tumors. This compound, chemically classified as a hydrochloride salt of daunorubicin, has garnered considerable attention in both clinical and preclinical research due to its potent cytotoxic effects on rapidly dividing cells. The unique structural features of Daunorubicin hydrochloride, characterized by an anthracycline core with a daunosamine sugar moiety, contribute to its remarkable ability to intercalate with DNA and inhibit topoisomerase II, thereby inducing DNA damage and apoptosis in cancer cells.

The clinical utility of Daunorubicin hydrochloride has been extensively documented in the management of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and certain types of lymphomas. Its efficacy as a single agent or in combination regimens has been a cornerstone in oncology therapy for decades. Recent advancements in drug delivery systems have further enhanced the therapeutic potential of this compound, leading to improved patient outcomes and reduced side effects. Nanoparticle-encapsulated formulations, for instance, have shown promise in targeted drug delivery, allowing for higher local concentrations at tumor sites while minimizing systemic toxicity.

In addition to its established clinical applications, Daunorubicin hydrochloride continues to be a subject of intense research for novel therapeutic strategies. One particularly promising area is its investigation as a potential chemosensitizer or radiosensitizer. Studies have demonstrated that the combination of Daunorubicin hydrochloride with other agents can enhance the efficacy of conventional cancer treatments. For example, preclinical data suggest that co-administration with specific kinase inhibitors or HDAC inhibitors can lead to synergistic effects by disrupting multiple aspects of cancer cell survival and proliferation.

The molecular mechanisms underlying the cytotoxicity of Daunorubicin hydrochloride have been extensively studied, revealing insights into its interaction with biological targets. The compound's ability to form stable complexes with DNA is mediated by its planar aromatic system, which facilitates intercalation between base pairs. This interaction disrupts normal DNA function, leading to the formation of DNA breaks and inhibiting DNA replication and transcription. Furthermore, recent research has highlighted the role of Daunorubicin hydrochloride in modulating epigenetic processes, suggesting that it may influence gene expression patterns beyond its primary DNA-damaging effects.

The development of resistance to anthracyclines remains a significant challenge in cancer therapy. However, ongoing research efforts are focused on overcoming this limitation through various approaches. One such approach involves the design of analogs or derivatives of Daunorubicin hydrochloride that retain or enhance their cytotoxic activity while reducing off-target effects. Structural modifications aimed at improving solubility or bioavailability have also been explored, with some derivatives showing improved pharmacokinetic profiles without compromising therapeutic efficacy.

The use of computational modeling and high-throughput screening techniques has accelerated the discovery of novel derivatives with enhanced properties. These methodologies allow researchers to predict the binding affinity and metabolic stability of candidate compounds, facilitating rapid optimization. Additionally, advances in biophysical techniques such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have provided detailed structural insights into the interactions between Daunorubicin hydrochloride and its biological targets, aiding in the rational design of more effective agents.

The environmental impact and sustainability considerations associated with the production and disposal of Daunorubicin hydrochloride are also gaining attention. Efforts are being made to develop greener synthetic routes that minimize waste generation and reduce reliance on hazardous reagents. Furthermore, research into biodegradable formulations or environmentally friendly drug delivery systems aims to address concerns regarding pharmaceutical waste management.

In conclusion, Daunorubicin hydrochloride, identified by the CAS number 23541-50-6, remains a vital therapeutic agent in modern oncology. Its broad spectrum of activity against various cancers underscores its importance in clinical practice. The continuous evolution in our understanding of its mechanisms of action, coupled with innovative drug delivery strategies and novel derivative development, ensures that this compound will remain at the forefront of cancer research for years to come.

23541-50-6 (Daunorubicin hydrochloride) Related Products

Recommended suppliers